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Abstract 
Purpose: To investigate the antinociceptive effect of the essential oil from the aerial parts of Gundelia. 
tournefortii (EOGT) in various experimental models 
Methods: The essential oil from the aerial parts of Gundelia tournefortii was extracted using steam 
distillation method median lethal dose (LD50) of EOGT was evaluated using the method of Lorke. 
Antinociceptive effect of EOGT in rats was carried out using chemical (formalin and acetic acid) and 
thermal (hot-plate) nociceptive tests at doses of 10, 31.6, 100, 316 and 1000 mg/kg. The possible 
mechanism of action of EOGT was also examined.  
Results: In acute toxicity test, LD50 for EOGT was 2500 mg/kg. EOGT at test doses (10, 31.6, 100, 316 
and 1000 mg/kg, orally) significantly reduced pain response in all tests in a dose-dependent manner 
(p < 0.05).  Glibenclamide (potassium channel sensitive to ATP antagonist) and yoimbina (α2 adrenergic 
receptor antagonist), partially antagonized the antinociceptive activity induced by EOGT. However, 
naloxone (opioid antagonist) and L-NAME (an inhibitor of nitric oxide synthase) did not reverse the 
antinociception produced by EOGT. 
Conclusion:  Essential oil from the aerial parts of G. tournefortii shows significant antinociceptive 
activity, which appeared to involve the participation of K+ channels sensitive to ATP and adrenergic 
receptors. These findings justify in part the traditional use of the plant in the treatment of various painful 
conditions. 
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Gundelia tournefortii L. commonly known in our 
region as "Akub", is a member of the Asteraceae 
(Compositae) family which grows in the semi-
desert area of Jordan and the Mediterranean 
areas including Palestine, Syria and Iraq during 
late winter and early spring. Gundelia tournefortii 
L is a spiny perennial herb thistle that is 
consumed as a fresh or cooked artichoke-like 
vegetable [1]. In Jordan Akub is sold along 
highways in the Northern part of the country as 
well as stores in Amman. Gundelia tournefortii  is 
usually employed in traditional medicines as a 
remedy to treat liver diseases, diabetes, chest 
pain, inflammation, gastric pain, vitiligo, diarrhea 
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and bronchitis [2-5]. In addition, G. tournefortii 
reduces fat and cholesterol content of the blood 
and is believed to have hypoglycemic and 
laxative properties [6]. In Turkey, it is proposed to 
enhance gingiva’s and used as an appetizer [7]. 
 
Phytochemical studies carried out with Gundelia  
tournefortii  have demonstrated the occurrence of 
many classes of constituents, including phenols, 
glycosides, tannins, flavonoids, carbohydrate, 
alkaloids, nitrate, and saponins [8]. Five known 
compounds (scopoletin, isopoletin, esculin and a 
mixture of ß-sitosterol and stigmasterol) were 
isolated and identified from G.  tournefortii. 
Furthermore, several essential oils from the 
aerial parts of G. tournefortii were identified by 
GC-MS analysis with terpinyl acetate, methyl 
eugenol, β-caryophyllene, thymol, p-cymene and 
γ-terpinene as the major oil components [9].  
 
Several studies have demonstrated that 
Gundelia tournefortii has pharmacological 
properties such as antibacterial activity [6], anti-
platelet activity [2], hepato-protective activity [10], 
hypolipemic activity [11], antioxidant activity [5], 
hypoglycemic activity [11], antiparasite activity, 
and anti-inflammatory activity [12]. Gundelia 
tournefortii also reduces some cardiovascular 
risk factors and decrease atherosclerosis [6,13]. 
 
Considering the popular use and because of the 
scarcity of pharmacological studies on the 
antinociceptive activity, this study investigated 
the chemical composition and antinociceptive 
activity as well as some of the possible 
mechanisms that underlie the antinociceptive 







Aerial parts of Gundelia tournefortii were 
collected during March to April period of 2015 
from Arbid (Jordan). The plant material was 
identified and authenticated by Associate 
Professor Yasen Zakaria, a taxonomist at 
Department of Biology. A voucher specimen was 
deposited under the number HU-2014-466 at the 
Hashemite University herbarium, Zarka, Jordan, 
for future reference. 
 
Determination of essential oil composition 
 
The essential oil from the dried aerial parts of 
Gundelia tournefortii was obtained by 
hydrodistillation for 8 h using a Clevenger-type 
apparatus according to Siani et al [14]. The 
essential oil of Gundelia tournefortii was 
performed by GC on a Trace GC ULTRA with 
FID detector gas chromatograph equipped with a 
column (30 m x 0.25 mm x 0.25 μm) type VB-5 
(methylpolysiloxane with 5 % of phenyl) and split 
injection. Mass spectrometry (MS) analysis was 
performed on a Polaris Q MS mass spectrometer 
(with an ion-trap at 70 eV). Column temperatures 
were programmed from 40 °C for 2 min, raised to 
180 °C at 4 °C.min-1. Helium was the carrier gas 
at 1.4 mL/min. The identification of volatile 
constituents of the essential oil (EO) was made 
by automated comparison of their mass spectra 
with that of the NIST (National Institute of 
Standards and Technology) library. 
 
Drugs and chemicals 
 
All chemicals and drugs were purchased from 
Sigma Chemical Co., St. Louis, MO, unless 
otherwise stated. All drugs were dissolved in 
sterile saline. The essential oil was prepared in 1 




Non-fasting male Wistar rats weighing between 
150 – 250 g or Swiss albino mice weighing 
between 25 - 35 g (only for acute toxicity 
experiment) were used. The animals were 
obtained from the Animal House, Department of 
biology, Faculty of Basic Sciences, Hashemite 
University. The animals were kept in an Animal 
House provided with a 12 h light/dark cycle at 22 
– 25 °C and free access to food and water ad 
libitum. All test solutions were administered in a 
volume of 10 ml/kg body weight. The animals 
were allowed to adapt to the laboratory for at 
least 2 h before testing and were used only once.  
Animal care and handling procedure were in 
accordance with the International Association for 
the Study of Pain guidelines for the use of 
animals in pain research [15]. Experimental 
protocols and procedures were approved by 
Research Ethics Committee of Hashemite 




The hot-plate test at 50 ± 1 °C was used as 
previously described by Qnais et al [16]. Latency 
to a discomfort reaction (licking paws) was 
determined in seconds before and 60 min after 
oral administration of vehicle (1 % v/v Tween 80 
in sterile saline), EOGT (10, 31.6, 100, 316 and 
1000 mg/kg) to 6 groups of male rats, (six 
animals per group). The 7th group received 
morphine intraperitoneally (5 mg/kg; positive 
control). The largest doses were determined on 
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the basis of LD50 experiments. The doses were 
calculated to be located at approximately 0.5 log 
units from each other on a log scale. The cut-off 
time was 60 s. The prolongation of the latency 
times was compared to the values of the control 
and used for statistical comparison. Baseline was 
considered as the mean of three readings of the 
reaction time obtained before administration of 
vehicle, EOGT or morphine and was defined as 
the normal reaction time of animals to this 
temperature. The increase over baseline (%) was 
calculated using Eq 1. 
 
Increase (%) = {(A – B)/B}100…………….. (1) 
 
where A is the mean of three readings of reaction 
time after treatment taken within 5 - 7 min; B is 
the mean of three readings of reaction time 
obtained before treatment. In this, and the 
following experiments, the inhibitory dose 50 % 
(ID50) was determined from the plot of individual 
experiments by the best visual fit.  
 
Acetic acid-induced abdominal writhing test 
 
This test was performed in rats as described by 
Matheus et al [17].Briefly, after an intraperitoneal 
administration of a 2 % (v/v) acetic acid solution 
in a volume of 0.1 ml/10 g body weight. The 
nociceptive behavior was quantified by counting 
the number of writhes, a response consisting of 
contraction of an abdominal wall, pelvic rotation 
followed by hind limb extension, during 
continuous observation for 20 min beginning 
from 5 min after the acetic acid injection. Rats 
were orally pre-treated 60 min before the 
administration of the nociceptive agent with 
EOGT (10, 31.6, 100, 316 and 1000 mg/kg), or 
vehicle (1 % Tween 80 in normal saline). A 
positive control group was composed of animals 
pre-treated with morphine (5 mg/kg, i.p.). 
Inhibitions of writhing was computed using Eq 2.  
 
Inhibition (%) = {(N – Nt}/N}100 …………… (2) 
 
where N is the mean number of stretching of 
control group and Nt is the mean number of 




Rats were divided into groups (six rats each) and 
were injected orally with either vehicle (1 % v/v 
Tween 80 in sterile saline) or EOGT (10, 31.6, 
100, 316 and 1000 mg/kg). A positive control 
group was composed of animals pre-treated with 
morphine (5 mg/kg, i.p.). Sixty min later, 50 μL of 
5 % formalin was injected subcutaneously into 
the dorsal surface of the right hind paw of each 
rat using a microsyringe with a 27 gauge needle. 
Immediately after formalin injection, animals 
were placed individually in acrylic observation 
chambers (320 cm2 × 40 cm). Mirrors were 
arranged at angles to allow clear observation of 
the paws of the animals. Licking of the injected 
paw was defined as the nociceptive response. 
The total time of the response was measured 
during the periods of 0 – 5 min (early phase) and 
15 – 40 min (late phase). Inhibition of licking (%) 
was calculated using Eq 3.  
 
Inhibition (%) = {(A – B)/A}100 ……….……(3) 
 
where A is the time of licking before treatment; B 
is the time of licking after treatment.  
 
Determination of possible mechanisms of 
antinociceptive action  
 
In order to evaluate the possible participation of 
opioid system, potassium channels sensitive to 
ATP, adrenergic system, and nitric oxide 
pathways in the antinociceptive action of EOGT, 
the animals pre-treated with antagonist naloxone 
(10 mg/kg), glibenclamide (2 mg/kg), yoimbina (1 
mg/kg), and L-NAME (3 mg/kg), respectively. 
Antagonists were administered i.p. 15 min before 
oral administration of vehicle (1 % v/v Tween 80 
in sterile saline) or the ED50 of EOGT. Using the 
acetic acid-induced abdominal writhing test, hot-
plate test, and the formalin test as described 
above, inhibition of the writhing response, latency 
times and licking was calculated after 60 min of 
vehicle (1 % v/v Tween 80 in sterile saline) or 
EOGT administration. 
 
Acute toxicity test 
 
Lethal dose (LD50) of the EOGT was evaluated in 
mice as described by Lorke [18]. Animals were 
randomly assigned to different groups containing 
5 mice in each group. EOGT (10, 100, 1000, 
2000, 3000 and 5000 mg/kg) was administered 
orally to six groups of mice, and the control group 
received 1 % v/v Tween 80 in sterile saline, (10 
ml/kg). The mice were allowed food and water ad 
libitum. Signs of toxicity and mortality within 72 h 




The data obtained are presented as mean ± 
SEM, and were analyzed using GraphPad Prism. 
Statistically significant differences between 
groups were calculated by the application of one-
way analysis of variance (ANOVA) followed by 
Duncan’s test for multiple comparisons. P < 0.05 
was chosen as the criterion of statistical 
significance. 
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Essential oil  
 
A total of 18 compounds, representing 88.4 % of 
the total oil content were identified (Table 1).  α-
Terpinyl acetate (15.2 %), eugenol (9.5 %), p-
cyme (9.5 %), β-caryophyllene (7.1%), and 
estragole (6.1%), were the major constituents 
(Table 1). 
 
Table 1: Constituents of essential oil of aerial parts of 
Gundelia tournefortii 
 
Constituent  (%) 
α-Tujone 



























α- Pinena  
α-Terpinyl acetate                                                                    
4.1 
15.2




The LD50 of the EOGT in mice was 2500 mg/kg 
indicating a low toxicity of the EOGT. No signs of 
toxicity, such as diarrhoea, motor impairment, 
ataxia, hyperactivity or alterations on respiratory 
frequency or piloerection, were noted in the 
control or experimental animals at lower doses. 
Also, no gastric ulcerogenic effect was observed 
in controls or treated animals. Severe 
depression, abnormal gait, ataxia, increased 
respiration and decreased activity were observed 
at dose higher than 3000 mg/kg 
 
Effect of EOGT on latency time 
 
In hot plate test, EOGT (10, 31.6, 100, 361 and 
1000 mg/kg, orally) significantly increased 
latency (time of response) to thermal stimulation 
in a dose-dependent manner compared with 
control (vehicle only) rats with ID50 value of 52.1 
± 3.2 mg/kg (Fig. 1). The percentage of increase 
in baseline produced by morphine (5 mg/kg, i.p.) 
was 85.1 ± 3.1%. 
 
Effect of EOGT on acetic acid-induced 
abdominal writhing 
 
The antinociceptive effect of EOGT on the 
writhing are shown in Figure 2. Administration of 
the EOGT orally at different doses (10, 31.6, 100, 
361 and 1000 mg/kg) caused an inhibition of the 
writhing response induced by acetic acid 
compared with control rats (vehicle only) (p < 
0.05). This inhibition was dose-dependent. The 
calculated mean ID50 value was 81.1 ± 2.4 
mg/kg. The percentage inhibitions of writhing 



















Control 1 1.5 2 2.5 3 Morphine









Figure 1: Effect of EOGT and morphine administration on the thermal nociception in rats submitted to the 
hotplate test. Values were expressed as mean ± SEM (n=6). Control value indicates the animals injected with 
vehicle and the asterisks denote the significance levels when compared with control groups (p > 0.05) 
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Figure 2: Effects of EOGT and morphine 
administration against acetic acid-induced writhing 
response in rats. Each column represents the mean of 
6 animals and the error bars indicate the SEM. Control 
value indicates the animals injected with vehicle and 
the asterisks denote the significance levels when 
compared with control groups (p > 0.05). 
 
Effect of EOGT on formalin-induced 
nociception   
 
The results in Fig. 3A and B demonstrate that 
EOGT (10, 31.6, 100, 361 and 1000 mg/kg, 
orally) significantly inhibited both the early 
(neurogenic, 0–5 min) and late (inflammatory, 
15–30 min) phases of formalin-induced licking 
compared with control rats. However, its 
antinociceptive effects were significantly more 
pronounced against the second (late) phase of 
this pain model. The calculated ID50 value for the 
first and second phases (respectively) were: 65.3 
± 2.6 and 85.1 ± 3.8 mg/kg, and the inhibitions 
observed were 58.1 ± 5.3% and 69.7 ± 6.9% at a 
dose of 1000 mg/kg, for the first and second 
phases, respectively (Fig. 3A and B). The 
percentage inhibitions of licking produced by 
morphine (5 mg/kg, i.p.) were 90.1 ± 7.5 and 
86.2 ± 4.4%, for the first and second phases, 
respectively. 
 
Possible mechanisms of antinociceptive 
action of Gundelia tournefortii  
 
Pretreatment of animals with antagonists 
glienclamide and yoimbina partially reversed the 
antinociceptive action of EOGT (Table 2). 
However, there was no reversal when the 
animals were pretreated with the naloxone and 




To date, several studies have been performed to 
investigate possible antinociceptive activities of 
medicinal plants. In the current study the 
antinociceptive activity of Gundelia tournefortii 
essential oil has been studied. Our data 
demonstrated that the EOGT elicited effective 
antinociceptive effects in rats as determined by 
acetic acid-induced abdominal writhing, formalin 
test and hot plate test. The experimental models 
used in this study were selected such that both 
centrally and peripherally mediated effects were 
measurable. The acetic acid-induced abdominal 
writhing elucidates peripheral effects; hot-plate 
test reveal central activity, while the formalin-
induced nociception test investigate both central 
and peripheral effects. We also used selective 
antagonists of several mediators involved in the 
nociception in an attempt to provide some insight 
into the mechanisms involved in EOGT 
antinociceptive properties. 
 
The hot-plate test is widely used for the 
evaluation of centrally acting analgesics material.  
In this test the behavioral responses as jumping, 
licking paws, pulling out of the paws can be 














Control 1 1.5 2 2.5 3 Morphine






















Control 1 1.5 2 2.5 3 Morphine









Figure 3: Effects of EOGT (10, 31.6, 100, 361 and 1000 mg/kg) and morphine (5mg/kg) administration on 
nociceptive responses to intraplantar injection of formalin in rats. Control values indicate vehicle administration, 
and the asterisks denote significance levels when compared with the control group (p > 0.01). Values were 
expressed as mean ± SEM (n = 6) 
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Table 2: Effect of naloxone, glibenclamide, yoimbina and L-NAME on EOGT antinociceptive activity in rats 
assessed using the hot-plate test, abdominal writhing test and formalin-induced pain test. Control indicates 
vehicle administration, and the one asterisk (*) denotes significance levels when compared with the control 
group. Two asterisks (**) denote significance levels when compared with the EOGT treated group (p > 0.01). 
Values were expressed as mean ± SEM (n=6) 
 
Treatment Increase in 
baseline 
(hotplate test, %) 
Inhibition (%) of 







Control 2.3±0.2 2.1±0.5 1.6±0.2 2.2±0.3 
EOGT 49.1±1.7* 50.1±2.5* 50.4±3.1* 51.1±2.7* 
Morphine 84±3.5* 88±2.3* 87±3.2* 86±2.4* 
Naloxone 2.1±0.4 1.4±0.7 2.2±0.7 5.1±0.8 
Naloxone + EOGT 49.3±1.8 52.1±2.1 50.1±2.2 51.7±1.3 
Morphine +Naloxone 
Glienclamide                                        
Glienclamide+ EOGT 
Yoimbina 































Doses of EOGT used were those used to give ID50 
 
Comparing values obtained for reaction time 
(licking time) of animals treated with EOGT 
extract and the control values both before and 
after treatment, it is clear that the EOGT extract 
caused a significant dose-dependent 
prolongation of latency times which indicates 
centrally mediated activity.  
 
The writhing test has long been used as a 
screening tool to evaluate antinociceptive 
properties of new substances [20,21]. In the 
writhing test, acetic acid activates peripheral 
nociceptors on the sensory nerve fibers by 
releasing pro-inflammatory substances. The 
nociceptive response in the acetic acid-induced 
abdominal constriction assay arises from 
synthesis of prostaglandins by the action of the 
constitutively expressed enzyme 
cyclooxygenase-2 (COX-2), which leads to 
hyperalgesia and pain. Non-steroidal anti-
inflammatory drugs like aspirin inhibit synthesis 
of prostaglandin resulting in the decrease 
sensitivity of the nociceptors to pain producing 
agents such as bradykinin. In this study EOGT at 
test doses (10, 31.6, 100, 316 and 1000 mg/kg, 
orally) caused a significant dose-dependent 
decrease in the number of acetic acid-induced 
writhes in rat in comparison to control. This 
observation indicates that EOGT possesses 
peripherally-mediated antinociceptive property 
and EOGT induced analgesic effect through 
mechanism linked partly to inhibition of 
prostaglandin synthesis. 
 
The formalin test identifies mainly centrally acting 
agents which inhibit both early and late phases 
almost equally. Injection of formalin induces a 
biphasic pain response; the first phase (short 
phase) is thought to result from direct activation 
of C-fiber afferent nociceptors.  After a short 
period, the acute phase is followed by a 
continuous prolonged response (Phase II) which 
is due to the combined effects of afferent input 
and central sensitization in the dorsal horn. A 
central sensitization of dorsal horn neurons 
occurs during inflammatory pain, In that phase 
amines (histamine and serotonin), 
prostaglandins, bradykinin and cytokines (e.g., 
TNF-a, IL-1b, IL-8) play the major role [22,23]. 
Suppression of both phases of nociception as 
observed with the EOGT extract in this study 
lends strong credence to the presence of both 
centrally and peripherally mediated effects. This 
speculation of dual activity is further buttressed 
by the significant activity observed in both the 
acetic acid-induced abdominal writhing and hot-
plate tests. 
 
The mechanisms by which the EOGT produced 
antinociception in the three models of 
nociception studied are not completely 
understood. The present results show, however, 
that EOGT acts partially by interaction with 
potassium channels sensitive to ATP and α2 
adrenergic receptor, because the antagonists 
glibenclamide (potassium channels sensitive to 
ATP antagonist) and yoimbina (α2 adrenergic 
receptor antagonist) partially  reduced EOGT 
antinociceptive activity when assessed against 
hot-plate test, abdominal writhing test and 
formalin-induced pain test. These results are 
consistent with several recent studies such as 
Abotsi et al [24].  Activation of opioids receptors 
is also important in modulating pain. Agonist of 
these receptors have significant antinociceptive 
effect that can be reversed by non-selective 
opioid receptor antagonist naloxone. However, 
this mechanism does not participate in EOGT 
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activity, because pretreatment animals with this 
non-selective opioid receptor antagonist 
naloxone did not reverse its. Another important 
pathway in modulation of nociception is the 
pathway for nitric oxide. In this regards, pre-
treatment with an inhibitor of nitric oxide 
synthase (L-NAME) 15 min before experiment, 
did not reverse the antinociception caused by 
EOGT. This observation suggests that nitric 
oxide pathway had no effect. Further study 
needs to understand the precise receptor (such 
as TRPV1 receptors, protein kinase C and 
others) participate in analgesic effect of EOGT. 
 
The antinociceptive effect of EOGT may be 
related to the presence of a number of 
constituents such as eugenol, p-cyme, β-
caryophyllene, and estragole in the essential oil 
extract. For example eugenol the major essential 
oil of Gundelia tournefortii (9.5 %) has been 
shown to possess anti-inflammatory, antioxidant, 
anaesthetic and muscle relaxant properties [25]. 
Previous study showed that eugenol exhibits 
antinociceptive effects through different 
mechanisms that may involve both central and 
peripheral pathway, One of these mechanisms, 
is via blockade of calcium channels and vanilloid 
receptor modulation [26]. Further study done by 
Dal Bó et al [27] proved that eugenol promotes 
significant antinociception by the inhibition of 
glutamatergic neurotransmission and cytokine 
signaling. A study done by Santana et al [28] 
showed that p-cymene (one of the principal 
compounds of essential oil of Gundelia 
tournefortii)  possesses peripheral and central 
antinociceptive properties as well as anti-
inflammatory activity and they suggest that p-
cymene act on the arachidonic acid cascade 





The present findings indicate that EOGT has 
analgesic effect arising from both CNS and 
peripheral actions and is related to its ability to 
activate potassium channels sensitive to ATP 
and α2 adrenergic receptors. Further studies are 
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